iRhythm Technologies (NASDAQ:IRTC) Stock Has Consensus Price Target of $164.07

iRhythm Technologies logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is broadly positive: 17 brokerages rate iRhythm Technologies “Moderate Buy,” and the average 12-month price target is $164.07. Recent target changes were mixed, ranging from Canaccord’s increase to $206 to cuts by Wells Fargo and Needham.
  • Quarterly earnings beat expectations: iRhythm reported earnings per share of $0.82 versus a $0.02 consensus estimate, while revenue of $221.59 million was slightly below forecasts but up 14.9% year over year.
  • The board authorized a $200 million share repurchase plan, allowing the company to buy back up to 6.7% of its shares.
  • MarketBeat previews the top five stocks to own by December 1st.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seventeen brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $164.07.

Several analysts have commented on the stock. Wells Fargo & Company decreased their price objective on shares of iRhythm Technologies from $150.00 to $135.00 and set an "overweight" rating for the company in a research note on Friday, November 6th. Needham & Company LLC cut their price objective on shares of iRhythm Technologies from $194.00 to $165.00 and set a "buy" rating on the stock in a research note on Friday, November 6th. Weiss Ratings cut shares of iRhythm Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, November 12th. Wall Street Zen cut shares of iRhythm Technologies from a "buy" rating to a "hold" rating in a report on Saturday, October 10th. Finally, Canaccord Genuity Group boosted their target price on shares of iRhythm Technologies from $196.00 to $206.00 and gave the company a "buy" rating in a research report on Friday, November 6th.

Check Out Our Latest Report on IRTC

iRhythm Technologies Price Performance

NASDAQ:IRTC opened at $94.24 on Friday. The company has a debt-to-equity ratio of 3.68, a current ratio of 3.57 and a quick ratio of 3.45. iRhythm Technologies has a 1 year low of $82.85 and a 1 year high of $192.47. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of -80.55 and a beta of 1.39. The business has a 50 day simple moving average of $109.62 and a 200-day simple moving average of $118.70.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.80. The firm had revenue of $221.59 million for the quarter, compared to the consensus estimate of $222.23 million. iRhythm Technologies had a positive return on equity of 26.88% and a negative net margin of 4.52%. The company's revenue for the quarter was up 14.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.06) earnings per share. Equities analysts forecast that iRhythm Technologies will post 0.79 EPS for the current year.

iRhythm Technologies declared that its Board of Directors has authorized a stock repurchase plan on Wednesday, November 11th that authorizes the company to repurchase $200 million in shares. This buyback authorization authorizes the company to reacquire up to 6.7% of its shares through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its shares are undervalued.

Insider Transactions at iRhythm Technologies

In other iRhythm Technologies news, Director Abhijit Talwalkar bought 7,900 shares of the company's stock in a transaction dated Thursday, November 19th. The shares were purchased at an average cost of $96.67 per share, for a total transaction of $763,693.00. Following the transaction, the director directly owned 7,900 shares of the company's stock, valued at approximately $763,693. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.98% of the company's stock.

Institutional Investors Weigh In On iRhythm Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRTC. Voya Investment Management LLC grew its stake in iRhythm Technologies by 3,578.5% in the 3rd quarter. Voya Investment Management LLC now owns 230,934 shares of the company's stock valued at $26,248,000 after acquiring an additional 224,656 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in iRhythm Technologies by 99.2% during the first quarter. The Manufacturers Life Insurance Company now owns 390,577 shares of the company's stock worth $46,096,000 after acquiring an additional 194,502 shares during the last quarter. Jump Financial LLC purchased a new stake in iRhythm Technologies in the 3rd quarter worth approximately $15,497,000. M&G PLC purchased a new position in shares of iRhythm Technologies during the 3rd quarter worth $13,905,000. Finally, USS Investment Management Ltd boosted its holdings in shares of iRhythm Technologies by 84.9% during the third quarter. USS Investment Management Ltd now owns 197,729 shares of the company's stock worth $22,465,000 after purchasing an additional 90,772 shares during the last quarter.

iRhythm Technologies Company Profile

(Get Free Report)

iRhythm Technologies is a medical technology company that develops digital solutions for detecting and monitoring heart rhythm disorders. Its services combine wearable electrocardiogram (ECG) devices with cloud-based data analysis and clinical reporting to help healthcare professionals assess patients for conditions such as cardiac arrhythmias. The company's Zio product line includes wearable ECG monitors, such as Zio XT, which records a patient's heart activity during an extended monitoring period. iRhythm also offers Zio AT, a monitoring service designed to provide clinicians with ECG data during the monitoring period.

Featured Articles

Analyst Recommendations for iRhythm Technologies (NASDAQ:IRTC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in iRhythm Technologies Right Now?

Before you consider iRhythm Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRhythm Technologies wasn't on the list.

While iRhythm Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines